Organisation - Management and Board



CEO Ulrika Hammarström Lüllmaa - holds a Master of Science in molecular biology as well as a postgraduate qualification in “Clinical Drug Development” from Uppsala University. Ulrika has worked in the CRO business since 2001 and has experience from positions such as CRA Manager, Clinical Project Leader and Country Manager. Ulrika Hammarstrom Lüllmaa holds the position of CEO at SCRO


Biostatistics and Data Management Manager Catarina Jansson Blixt - Responsible for the biostatistics and data management activities in all in-house projects. Acting study biostatistician and as such involved in for example the development of study protocols, SAPs (Statistical Analysis Plans) and clinical study reports.

Catarina has 25 years of experience in Clinical trials. She started her career at Medical Products Agency where her main duties consisted of reviewing phase II-IV study protocols and to act as a discussing partner for the industry and Investigators in statistical issues. In 2001 she was hired to build the new Nordic Biometrics department at Pfizer AB and during her seven years she successfully held responsibility for the biostatistics activities in all clinical trials within the Nordic countries.


Clinical Operation Manager, Marie Wiklander - responsible for the clinical trial management services and resourses.

Marie has more than 25 years of experience in Pharmaceutical Development in various companies/authority and positions of which 14 years of experience in clinical trials in different therapeutic areas. She has been in various positions at both R&D sites (Pharmacia and Q-Med/Galderma) and CRO (Quintiles). These positions included e.g. global study program management, protocol development, coordination of study teams, negotiation/cooperation with CRO, monitoring and handling of study documentation, applications.

The past 13 years Marie has been in management positions, Clinical Operation Manager at Q-Med, Manager at Quality Assurance Department at Q-Med and her latest position was Head of Section at Regulatory Administration (New application) at the Medical Products Agency.


Ulf Boberg,  Chairman of the Board

Ulf holds a Master's degree in Pharmacy, a Ph.D. in Physiology, and a Master’s degree in Business Development and Economics (MBAexec), all at Uppsala University.

Ulf was a medical director at Gambro AB in the late 80's and then CEO of PMC Clinical Research AB, who commissioned clinical trials for international pharmaceutical companies. He has been active as CEO and business developer in many companies in pharmacological and medical development since 1993. Ulf was recruited in 1998 as Deputy CEO and Development Manager of Astra Pain Control, and went on to other assignments following the merger with Zeneca in 1999.


Since 2000, Ulf has been active as CEO of a number of small pharmaceutical and biotechnology companies: Global Genomics AB, Affibody AB, and Creative Antibiotics AB. Ulf worked as a consultant with 'Tissue Re-engineering' for NovaHep AB 2013–2014. Ulf was CEO of Miris Holding AB from 2014 to 2016. He has been Chairman of the Board of Alfta Rehab Center, Trial Form Support AB, iNovacia AB (today Kancera AB), and SpectraCure AB.


Jens Mattsson - is a trained economist with a background in banking and insurance. He has worked at SEB for 10 years and held positions such as asset manager as well as various other management positions. Currently Jens acts as economic adviser to the former owners of Radi Medical. He sits on a number of boards one of which is AprioMed.



Thomas Lüllmaa - partner and CEO of Riksmäklaren, a family business in Uppsala with a 35-year history. In addition, Thomas is a partner in several real estate companies and a member of several boards in the property management and clothing industries.



Ulrika Hammarström Lüllmaa - see above.


Senior Advisor -  Bengt Gustavsson holds a MSc in Pharmacy (1987) and a Dr Med Sci/Pathology (1994) from Uppsala university. Bengt also holds a Dipl. Pharm. Med. from the Swiss Association of Pharmaceutical Professionals and the EUCOR-universities in Basel, Freiburg and Strasbourg. He has worked in the pharmaceutical industry for almost 24 years, and has among other positions been Nordic Clinical Research Director at Sanofi-Aventis, Nordic Medical Director at Novartis Oncology and Nordic Medical Director at Celgene. Since the summer of 2017 he is Head of Medical Relations at Oncopeptides AB, a board director at Nanexa AB, and owner and CEO of Sangus Jazz AB. Bengt has primarily worked within oncology and hematology, and has been working with clinical research studies in phase I - III, translational research projects, as well with various kinds of phase IV- and post marketing surveillance-studies. He has been involved in the clinical research and launch of 14 different drug substances that have been approved.